PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE USING DOS

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 扩散光学成像和光谱（DOI，DOS）是新兴的诊断技术，定量测量浓度的脱氧血红蛋白，氧合血红蛋白，水，和脂质在厘米厚的组织。 在早期临床研究中，DOI和DOS已被用于表征乳腺肿瘤的生化组成和监测新辅助化疗患者的治疗反应。 在这项工作中，我们调查是否DOS测量早期获得的新辅助化疗方案可以预测最终，术后病理反应乳腺癌患者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Diffuse Optical Imaging and Spectroscopy (DOI, DOS) are emerging diagnostic techniques that quantitatively measure the concentration of deoxy-hemoglobin, oxy-hemoglobin, water, and lipid in cm-thick tissues. In early-stage clinical studies, DOI and DOS have been used to characterize breast tumor biochemical composition and monitor therapeutic response in neoadjuvant chemotherapy patients. In this work, we investigate whether DOS measurements obtained early in a neoadjuvant chemotherapy regimen can predict final, post-surgical pathological response in breast cancer patients.